Suchergebnisse - "Bates, Breanna M"

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy von Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Rodgers Suarez, Magdalia, Ruskin, Susan L, Greenberg, Philip D

“… BackgroundIn the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations …”
Volltext

Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells von Manzo, Teresa, Prentice, Boone M, Anderson, Kristin G, Raman, Ayush, Schalck, Aislyn, Codreanu, Gabriela S, Nava Lauson, Carina B, Tiberti, Silvia, Raimondi, Andrea, Jones, Marissa A, Reyzer, Michelle, Bates, Breanna M, Spraggins, Jeffrey M, Patterson, Nathan H, McLean, John A, Rai, Kunal, Tacchetti, Carlo, Tucci, Sara, Wargo, Jennifer A, Rodighiero, Simona, Clise-Dwyer, Karen, Sherrod, Stacy D, Kim, Michael, Navin, Nicholas E, Caprioli, Richard M, Greenberg, Philip D, Draetta, Giulio, Nezi, Luigi

“… CD8+ T cells are master effectors of antitumor immunity, and their presence at tumor sites correlates with favorable outcomes. However, metabolic constraints …”
Weitere Angaben

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy von Oda, Shannon K, Anderson, Kristin G, Ravikumar, Pranali, Bonson, Patrick, Garcia, Nicolas M, Jenkins, Cody M, Zhuang, Summer, Daman, Andrew W, Chiu, Edison Y, Bates, Breanna M, Greenberg, Philip D

“… Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can …”
Weitere Angaben

Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer von Alencar, Gabriel F, Mohamed, Asmaa O, Burnett, Madison G, Jean, Samantha St, Nelson, Anders R, Su, Yapeng, Voillet, Valentin, Bates, Breanna M, Rodgers Suarez, Magdalia, Ruskin, Susan L, Trieu, Lam, Lam, Jennifer L, Bekiranov, Stefan, Gottardo, Raphael, Greenberg, Philip D, Anderson, Kristin G

“… The five-year survival rate for ovarian cancer patients remains below 50%, underscoring the need for innovative therapies. One promising approach involves …”
Weitere Angaben

Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease von Morse, Christopher B., Voillet, Valentin, Bates, Breanna M., Chiu, Edison Y., Garcia, Nicolas M., Gottardo, Raphael, Greenberg, Philip D., Anderson, Kristin G.

“… Mouse models of ovarian cancer commonly transfer large numbers of tumor cells into the peritoneal cavity to establish experimental metastatic disease, which …”
Volltext

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer von Anderson, Kristin G, Voillet, Valentin, Bates, Breanna M, Chiu, Edison Y, Burnett, Madison G, Garcia, Nicolas M, Oda, Shannon K, Morse, Christopher B, Stromnes, Ingunn M, Drescher, Charles W, Gottardo, Raphael, Greenberg, Philip D

“… Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian …”
Weitere Angaben

803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer von Anderson, Kristin G, Su, Yapeng, Burnett, Madison G, Bates, Breanna M, Suarez Gutierrez, Magdalia L, Ruskin, Susan L, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D

“… BackgroundOver 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last 30 …”
Volltext

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy von Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Magdalia Rodgers Suarez, Ruskin, Susan L, Greenberg, Philip D

“… Background: In the U.S., more than 50% of ovarian cancer patients die within 5 years of diagnosis, highlighting the need for innovations such as engineered T …”
Volltext